Preimplantation Genetic Testing Market Set to Reach US$999.2

Preimplantation Genetic Testing Market

The global preimplantation genetic testing (PGT) market is poised for substantial growth, with an expected value of US$552.7 million by 2025, progressing to US$999.2 million by 2032, growing at a CAGR of 8.8%. The surge in market demand is primarily driven by increasing adoption of assisted reproductive technologies (ART), technological advancements in genetic testing, and heightened awareness about genetic disorders and fertility treatments. With more individuals and couples seeking ways to prevent hereditary diseases and improve reproductive outcomes, PGT has emerged as a critical component in IVF (in vitro fertilization) procedures.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34757

Key Industry Highlights

The growing prevalence of genetic disorders, rising infertility rates, delayed childbearing, and technological advancements are key factors fueling market growth. The integration of personalized medicine and precision in fertility treatments offers new opportunities for market players. Furthermore, the expansion of healthcare infrastructure and improved accessibility of PGT kits and automated platforms are expected to accelerate the global adoption of preimplantation genetic testing.

Market Dynamics

Driver – Expanding Use of Assisted Reproductive Technologies (ART)

The increasing use of ART, particularly in developed nations, has substantially raised demand for PGT services. ART procedures, including IVF, are becoming increasingly common as more individuals and couples seek reproductive solutions. The integration of PGT into IVF protocols enhances the chances of successful pregnancies by selecting embryos with normal chromosomal structures, thus reducing the risk of miscarriage and other complications. As ART cycles increase globally, the need for PGT, especially aneuploidy screening (PGT-A), has risen accordingly.

In the U.S., ART cycles have surged in recent years. According to data from the CDC, U.S. fertility clinics conducted 435,426 ART cycles in 2022, marking a significant increase from 326,468 cycles in 2020. Given this upward trend, the role of PGT in ART is increasingly vital for ensuring the selection of healthy embryos, further driving market growth.

Restraint – Risk of Embryo Damage Limits Adoption

Despite the growing demand for PGT, several factors hinder its widespread adoption. The potential risk of embryo damage during the biopsy process is a significant limitation. Embryo biopsy, performed at the blastocyst stage, is essential for genetic testing, but it can result in complications, such as an increased risk of preeclampsia or preterm birth. Although PGT is generally safe, there are concerns related to diagnostic accuracy. For example, false positives can lead to the discarding of viable embryos, which can be detrimental to IVF outcomes.

The case of Monash IVF in Australia, which settled a $56 million class-action lawsuit over PGT-A misclassifications, highlights the challenges posed by diagnostic inaccuracies. Such cases underscore the need for improved testing protocols and enhanced accuracy to build trust in PGT services.

Opportunity – Technological Advancements in Genetic Analysis

Technological innovations, particularly next-generation sequencing (NGS) and artificial intelligence (AI), are revolutionizing the PGT market. NGS has enabled high-resolution chromosomal analysis, improving the accuracy of genetic testing and IVF success rates, especially for women of advanced maternal age. AI-powered tools for embryo selection, such as convolutional neural networks (CNNs), are also transforming the way fertility clinics assess embryo viability, further improving pregnancy outcomes.

Moreover, the development of non-invasive PGT techniques using cell-free DNA from spent culture media minimizes embryo damage and boosts testing accuracy. By integrating AI and NGS, these advancements offer significant growth potential for the market, promising to enhance the clinical efficacy of PGT procedures and broaden their applicability.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/preimplantation-genetic-testing-market.asp

Category-Wise Analysis

Product Insights

In the PGT market, genetic testing kits have gained significant traction due to their user-friendliness and standardized protocols. These kits are designed to streamline the testing workflow, reduce human error, and increase the accuracy of genetic analysis, making them an essential tool in IVF procedures. Kits also provide pre-validated reagents and optimized protocols that ensure consistency and reliability, making them highly attractive to fertility clinics.

With the growing demand for IVF services globally, particularly in developed markets, kits have become a scalable solution, ensuring broader adoption of PGT. Their compatibility with automated systems further enhances their efficiency, positioning them as a key product in the PGT market.

Application Insights

The aneuploidy application segment dominates the PGT market, accounting for 41.0% of market revenue in 2024. This dominance is attributed to the high prevalence of chromosomal abnormalities, particularly in older women, where the risk of miscarriage and implantation failure is significantly higher. Aneuploidy testing identifies abnormal chromosomal structures in embryos, improving the selection process and enhancing IVF success rates.

Aneuploidy testing remains the fastest-growing segment, driven by the adoption of next-generation sequencing technologies and a growing awareness of the benefits of genetic screening. The increasing acceptance of PGT-A in clinical practice further propels the demand for this testing.

Regional Insights

North America Preimplantation Genetic Testing Market Trends

North America is the leading region in the PGT market, with the U.S. contributing significantly to market growth. The increasing use of ART, rising maternal age, and growing awareness of genetic screening for hereditary disorders are key factors driving the demand for PGT. The presence of leading fertility clinics, substantial investment in genetic research, and favorable reimbursement policies further support market expansion in the region.

In addition, strong regulatory support and continuous collaboration between academic institutions and diagnostic companies foster innovation, solidifying North America’s position as a global leader in PGT technology.

Europe Preimplantation Genetic Testing Market Trends

Europe is witnessing steady growth in the PGT market, driven by rising IVF adoption rates, increasing awareness of genetic disorders, and technological advancements in genetic testing. The United Kingdom is expected to record the highest CAGR in Europe from 2025 to 2032, supported by favorable healthcare policies, increased access to fertility treatments, and a growing focus on precision medicine.

The region benefits from the presence of established diagnostic companies and robust healthcare infrastructure, which helps in promoting the accessibility and affordability of PGT services.

Asia-Pacific Preimplantation Genetic Testing Market Trends

Asia-Pacific represents a significant growth opportunity for the PGT market, driven by improvements in healthcare infrastructure, increasing access to fertility care, and changing social norms surrounding delayed parenthood. Countries like China, India, and Japan are witnessing a rise in infertility rates and a growing awareness of ART, leading to a higher demand for genetic screening. Additionally, the rise of local manufacturers offering cost-effective PGT kits and reagents is enhancing accessibility and affordability, further promoting market growth in the region.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34757

Competitive Landscape

The PGT market is highly competitive, with a mix of established players and emerging biotech firms striving to innovate and expand their offerings. Key players in the market focus on advancing genetic testing technologies such as next-generation sequencing (NGS) and AI-driven embryo analysis to improve test accuracy and efficiency.

Strategic collaborations, mergers, and acquisitions are common as companies aim to broaden their product portfolios and enhance global reach. There is also an increasing focus on developing automated platforms and user-friendly kits to meet the operational needs of fertility clinics, which is expected to intensify competition within the market.

Key Industry Developments

In January 2025, Illumina, Inc. launched major upgrades to its NovaSeq X Series, featuring a new single-flow-cell system and enhanced reagent kits, reinforcing its leadership in the genomic sequencing space.

In September 2024, CooperSurgical introduced an FDA-approved, single-hand-use inserter for Paragard®, improving usability and streamlining the insertion process for healthcare providers.

Key Players:

Thermo Fisher Scientific, Inc.

CooperSurgical, Inc.

Illumina, Inc.

Abbott

Agilent Technologies, Inc.

Medicover Genetics

Revvity Inc.

Takara Bio Inc.

Genea BIOMEDX

SeraCare Life Sciences

Shiva Scientific Company

Conclusion

The preimplantation genetic testing market is poised for robust growth, driven by increasing adoption of assisted reproductive technologies, advancements in genetic testing, and growing awareness of genetic disorders. As technological innovations, such as next-generation sequencing and AI-driven embryo analysis, continue to evolve, the market will experience further expansion, creating opportunities for both established and emerging players in the fertility industry. However, challenges such as embryo biopsy risks and diagnostic inaccuracies must be addressed to ensure broader adoption and long-term market success. With continuous advancements in genetic analysis and supportive regulatory frameworks, the future outlook for the preimplantation genetic testing market remains promising.

Preimplantation Genetic Testing Market Set to Reach US$999.2

Tags: